Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398150 · ClinicalTrials.gov registry record · NA
Cranberry Enhances Human Immune Function and Reduces Illness
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT01398150: Completed NA study, sponsored by University of Florida.
NCT01398150 is a NA study that has completed, run by University of Florida. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01398150, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether consuming a beverage made with cranberry polyphenols and proanthocyanidins is effective in modifying immune function by enhancing immune cell proliferation, cytokine production, and antioxidant capacity. If immune cell proliferation is improved, the subjects are expected to have fewer cold and flu symptoms.
Primary Outcome
Proliferation of γδ-T cells when cultured ex vivo in autologous serum
Interventions
- DIETARY_SUPPLEMENT Beverage made to look like the cranberry beverage
- DIETARY_SUPPLEMENT Beverage made from cranberry compounds
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-05 |
| Phase | NA |
What the finished NCT01398150 record still lists
NCT01398150 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Beverage made to look like the cranberry beverage is the first listed.
NCT01398150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01398150 about?
NCT01398150 is a clinical study titled "Cranberry Enhances Human Immune Function and Reduces Illness". The purpose of this study is to determine whether consuming a beverage made with cranberry polyphenols and proanthocyanidins is effective in modifying immune function by enhancing immune cell proliferation, cytokine production, and antioxidant capacity. If immune cell proliferation is improved, the ...
What is the current status of trial NCT01398150?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2009-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT01398150?
The interventions under investigation include: Beverage made to look like the cranberry beverage (DIETARY_SUPPLEMENT), Beverage made from cranberry compounds (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01398150?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01398150's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia